Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays

Clinical Breast Cancer

Volumn 5, Issue 5, 2004, Pages 385-392

  Cowherd, Stacy M ^a   Espina, Virginia A ^a   Petricoin III, Emanuel F ^b   Liotta, Lance A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Molecular profiling; Protein pathways; Signaling protein; Targeted therapy

Indexed keywords

ATM PROTEIN; CASPASE 7; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

APOPTOSIS; BIOLOGICAL MONITORING; BREAST CANCER; CANCER THERAPY; CELL POPULATION; CELL SURVIVAL; CLINICAL TRIAL; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALIZATION; LASER CAPTURE MICRODISSECTION; MICROENVIRONMENT; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 12144253621     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.046     Document Type: Article

References (54)

1. Holland JF, Frei E III, Bast R, Jr. et al. Cancer Medicine 4th ed. Baltimore: Williams & Wilkins; 1997.
2. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1:683-695.
3. Handermarck H, Vercoutter-Edouart AS, Revillion F, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001; 1:1216-1232.
4. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20:1981-1989.
5. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001; 8:47-61.
6. Simone NL, Paweletz CP, Charboneau L, et al. Laser capture microdissection: beyond functional genomics to proteomics. Mol Diagn 2000; 5:301-307.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
8. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411:375-379.
9. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 1998; 95:1050-1055.
10. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59:5002-5011.
11. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001; 286:2211-2214.
12. Espina V, Dettloff KA, Cowherd S, et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004; 4:83-93.
13. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3:317-325.
14. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 317-322.
15. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17:2941-2953.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
17. Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001; 292:929-934.
18. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997; 18:533-537.
19. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002; 62:6740-6749.
20. Ornstein DK, Gillespie JW, Paweletz CP, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000; 21:2235-2242.
21. Wulfkuhle JD, McLean KC, Paweletz CP, et al. New approaches to proteomic analysis of breast cancer. Proteomics 2001; 1:1205-1215.
22. Bonner RF, Emmert-Buck M, Cole E, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997; 278:1481-1483.
23. Curran S, Murray GI. Tissue microdissection and its applications in pathology. Curr Diagn Pathol 2002; 8:183-192.
24. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3:2091-2100.
25. Charboneau L, Scott H, Chen T, et al. Utility of reverse phase protein arrays: Applications to signaling pathways and human body arrays. Briefings Functional Genomics Proteomics 2002; 1:305-315.
26. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996; 274:998-1001.
27. Oesterreich S, Allredl DC, Mohsin SK, et al. High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer 2001; 84:493-498.
28. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003; 100:5974-5979.
29. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for imitator phenotype and breast cancer pathogenesis. Cancer Res 2000; 60:3884-3892.
30. Sgroi DC, Teng S, Robinson G, et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999; 59:5656-5661.
31. Sugiyama Y, Sugiyama K, Hirai Y, et al. Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 2002; 117:109-116.
32. Fuller AP, Palmer-Toy D, Erlander MG, et al. Laser capture microdissection and advanced molecular analysis of human breast cancer. J Mammary Gland Biol Neoplasia 2003; 8:335-345.
33. Kurose K, Hoshaw-Woodard S, Adeyinka A, et al. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001; 10:1907-1913.
34. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607-616.
35. Ahram M, Flaig MJ, Gillespie JW, et al. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003; 3:413-421.
36. Gillespie JW, Best CJ, Bichsel VE, et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 2002; 160:449-457.
37. Emmert-Buck MR, Strausberg RL, Krizman DB, et al. Molecular profiling of clinical tissue specimens: feasibility and applications. Am J Pathol 2000; 156:1109-1115.
38. Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001; 1:1271-1278.
39. Ge H. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res 2000; 28:e3.
40. Lueking A, Horn M, Eickhoff H, et al. Protein microarrays for gene expression and antibody screening. Anal Biochem 1999; 270:103-111.
41. Arenkov P, Kukhtin A, Gemmell A, et al. Protein microchips: use for immunoassay and enzymatic reactions. Anal Biochem 2000; 278:123-131.
42. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001; 2:research0004.1-0004.13.
43. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
44. Templin MF, Stoll D, Schrenk M, et al. Protein microarray technology. Drug Discov Today 2002; 7:815-822.
45. Wilson DS, Nock S. Recent developments in protein microarray technology. Angew Chem Int Ed Engl 2003; 42:494-500.
46. Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov Today 2002; 7(18 suppl):S143-S149.
47. MacBeth G, Schreiber SL. Printing proteins as microarray for high-throughput function determination. Science 2000; 5485:1760-1763.
48. Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17:301-307.
49. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol 2003; 7:55-63.
50. Humphery-Smith I, Wischerhoff E, Hashimoto R. Protein arrays for assessment of target selectivity. Drug Discov World 2002; 1:17-27.
51. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3:2085-2090.
52. Espina V, Mehta AI, Taylor T, et al. Clinical proteomics: technology for monitoring drug treatment effects on in vivo signal pathways in cancer cells obtained by biopsy. Proc Am Assoc Cancer Res 2003; 94:677 (Abstract #2963).
53. Petricoin EF III, Bischel VE, Calvert VS, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 2005 (In press).
54. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27(5suppl 9):13-19.